Table 1.

Examples of public-private partnerships within Johnson & Johnson's Global Public Health.

	PPP with Johnson & Johnson's GPH involvement	Indication
EU PPPs	Innovative Medicines Initiative (IMI) Corona Accelerated R&D in Europe (CARE) consortium (https://www.imi-care.eu/)	COVID-19 antiviral small molecules and antibodies
	IMI2 academia and industry united innovation and treatment for tuberculosis (UNITE4TB) (https://www.imi.europa.eu/projects-results/project-factsheets/unite4tb)	Tuberculosis antimicrobials
	Vlaams Agentschap voor Innoveren & Ondernemen (VLAIO)	Dengue antiviral and broad-spectrum flavivirus antiviral
	Wellcome Trust
	The University Leuven (KU Leuven)
	Heidelberg University (HU)
Asian PPPs	National Medical Research Council (NMRC) in Singapore	Dengue antiviral
	National University of Singapore in conjunction with Duke University (UK) (Duke-NUS)
	Johnson & Johnson Satellite Center for Global Health Discovery at Singapore's Duke-NUS Medical School, jointly established by Duke University and the National University of Singapore (Duke-NUS)	Broad-spectrum flavivirus antivirals
USA PPPs	Biomedical Advanced Research and Development Authority (BARDA) (https://aspr.hhs.gov/AboutASPR/ProgramOffices/BARDA/Pages/default.aspx)	COVID-19 antiviral and vaccine
	Medicines for Malaria Venture (MMV) (https://www.mmv.org/)	Long-acting anti-malarial drug

COVID-19, coronavirus disease 2019; EU, European Union; GPH, Global Public Health; PPP, public-private partnership; R&D, research and development; USA, United States of America.